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CLINICAL INVESTIGATION
Expression of Fas antigen and Bcl-2 in human glomerulonephritis
TSUKASA TAKEMURA, KATSUMI MuicMI, HIR0FuMI MIYAZATO, KAZURO YAGI,
and KAzuo YosHIoI
Department of Pediatrics, Kinki University School of Medicine, Osaka-sayama 589, Japan
Expression of Fas antigen and Bcl-2 in human glomerulonephritis. To
understand the regulatory mechanism of apoptosis in human glomerulo-
nephritis, we examined the expression of Fas antigen (CD95) and Bcl-2 in
five normal human kidney specimens and 80 tissues from patients with
several types of glomerular diseases. These proteins were detected in
glomeruli by immunofluorescence. The number of intraglomerular cells
positive for Fas antigen was high in Henoch-Schönlein purpura nephritis
and lupus nephritis, and that of Bcl-2-positive intraglomerular cells was
high in lupus nephritis, focal glomerular sclerosis, and IgA nephritis.
Dual-labeling and staining on serial sections indicated that mesangial cells
and occasionally infiltrating leukocytes expressed Fas antigen and Bcl-2. In
situ hybridization detected Bcl-2 mRNA in glomerular cells. Electron
microscopy revealed apoptotic cells and apoptotic bodies in proliferated
mesangial areas and within the glomerular capillaries. Fragmented DNA
was detected in glomeruli by in situ nick end labeling, the data of which
paralleled the number of Fas antigen-positive intraglomerular cells. In
mesangial proliferative types of glomerulonephritis, the population of
Bcl-2-positive intraglomerular cells, but not that of Fas antigen-positive
cells, was significantly correlated with the number of proliferating cell
nuclear antigen-positive glomerular cells, the grade of mesangial cell
increase, and the magnitude of proteinuria. This study showed that Fas
antigen and Bcl-2 are up-regulated in the glomeruli of several types of
human renal diseases. Bcl-2 overexpression might play a role in the
prolonged proliferation of mesangial cells and glomerular hypercellularity
in glomerulonephritis.
Apoptosis or programmed cell death plays a crucial role in
embryology, immunology and neoplasia [1, 2]. In the kidney,
apoptotic cell death has been observed in glomeruli of prolifera-
tive types of human glomerulonephritis [3], and in mesangial cells
of anti-Thy 1 antibody-induced glomerulonephritis [4, 5]. It is
likely that apoptosis of infiltrating leukocytes and intrinsic cells in
the inflamed glomeruli is a mechanism for the clearance of such
cells, thus promoting resolution from glomerular injury. Recovery
from proliferative glomerulonephritis occurs in several human
renal diseases, such as post-streptococcal acute glomerulonephri-
tis and Henoch-Schönlein purpura nephritis [6]. On the other
hand, in most chronic forms of human glomerulonephritis, intrin-
sic glomerular cells, particularly mesangial cells, persistently pro-
liferate. It is postulated that the mechanism for inhibiting apop-
totic cell death plays a role in the progression of glomerular injury
in those types of glomerulonephritis.
The protein encoded by the Bcl-2 (B-cell lymphoma/leuke-
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mia-2) protooncogene is a critical regulator of apoptosis and can
block apoptotic cell death and prolong the lifespan of lymphoid
cells [7—9]. The expression of Bcl-2 is not specific to neoplastic
lymphoid nodes, and it has been identified in a number of
nonhematolymphoid tissues [10—12].
There are no precise descriptions of the expression of Fas
antigen (APO-1/CD95) and Bcl-2 protein in human glomerulone-
phritis. Here, we studied the expression of Fas antigen and Bcl-2
mRNA and protein in patients with various glomerular diseases.
Methods
Tissues
Kidney tissue specimens were obtained by percutaneous needle
or surgical biopsy from 80 patients with glomerular diseases: 12
had minimal change nephrotic syndrome, 7 had focal glomerular
sclerosis, 38 had IgA nephritis, 10 had mesangial proliferative
(IgA-negative) glomerulonephritis, 7 with Henoch-Schönlein pur-
pura nephritis and 6 with lupus nephritis (WHO Class IV) [13].
Laboratory data including urinalysis, 24-hour protein excretion,
and creatinine clearance were collected from each patient. Most
of the patients, excluding three with focal glomerular sclerosis,
Fig. 1. The proportion of intraglomerular cells positive for (l Fas antigen
and Bcl-2 () protein in various glomerular diseases. Positive cells per
glomerular cross section are expressed as means SD. Abbreviations are:
MCNS, minimal change nephrotic syndrome; FGS, focal glomerular
sclerosis; IgA N, IgA nephritis; Mes Pro GN, mesangial proliferative
(IgA-ncgative) gtomerulonephritis; HSPN, Henoch-Schönlein purpura
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Fig. 2. Immunofluorescent staining for Fas antigen and Bcl-2 protein in tissues from patients with IgA nephritis. A. Cellular staining for Fas antigen. B. Fas
antigen and type IV collagen were double-stainied with fluorescein- and rhodamine-labeled secondary antibodies, and photographed at the same time.
The glomerular and tubular basement membranes, mesangium, and Bowman's capsules are stained for type IV collagen. Fas antigen-positive cells are
located in the mesangial area. C. Bcl-2 protein-positive cells in a glomerulus. D. Double staining of Bcl-2 and type IV collagen, photographed at the
same time. Positive cells are localized in the mesangial area and within the capillary walls. Long arrows denote positive cells and short arrows in A and
C the Bowman's capsule. Abbreviation is G, glomerulus. Original magnification: A—D, >< 400.
three with IgA nephritis and two with lupus nephritis, had normal
creatinine clearance. Five other renal specimens with no morpho-
logic abnormalities under light and immunofluorescent micros-
copy was obtained either by biopsy from two patients with
macroscopic hematuria or during the course of surgical manage-
ment from three patients with renal calculi or renal trauma, were
used as normal kidney tissues. For immunofluorescence all the
kidney specimens were snap-frozen in isopentane precooled in
liquid nitrogen, and stored at —70°C until use.
The tissues were stained with hematoxylin-eosin and periodic
acid-Schiff's reagents. The severity of pathologic features in the
glomeruli, tubules and interstitium was assessed upon light micro-
scopic observation. Glomerular hypercellularity, mesangial matrix
increase, and tubulointerstitial changes were graded semiquanti-
tatively on a 0 to 3+ scale (absent or minimal, mild, moderate,
and marked) as described [141. The percentage of glomeruli
involving crescents or global sclerosis/hyalinosis was also deter-
mined. Mesangial hypercellularity was mild in patients with
mesangial proliferative (IgA-negative) glomerulonephritis, com-
pared with that in patients with IgA nephritis.
For conventional electron microscopy, a portion of the kidney
tissue was fixed in 2% glutaraldehyde, washed in PBS, postfixed in
1% osmic acid, and then embedded in Epon 812. Ultrathin
sections were cut, and stained with lead citrate and uranyl acetate
[15].
Antibodies
The following antibodies were used for immunocytochemistry:
mouse monoclonal antibody to Bcl-2 protein [12] (Cambridge
Research Biochemicals, London, UK), mouse monoclonal anti-
body to human Fas antigen (MBL, Nagoya, Japan) [16], mouse
monoclonal antibody to proliferating cell nuclear antigen (PCNA;
Oncogene Science, Inc., Uniondale, NY, USA), mouse monoclo-
nal antibody to human leukocyte common antigen (LCA) (CD45;
DAKO, Grostrup, Denmark), and rabbit antibody to human type
IV collagen (Advance, Tokyo, Japan). Fluorescein-isothiocyanate
(FITC)-labeled goat anti-mouse IgG, peroxidase-labeled goat
anti-mouse IgG, rhodamine-conjugated goat anti-rabbit IgG were
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Fig. 3. Electron microscopy of apoptotic cells
and apoptotic bodies in glomeruli of patients with
lupus nephritis (WHO Class IV). Condensed
nuclei (asterisks) are present within the
mesangial area (A) and capillary lumen (B).
Original magnification: A and B, X 5,000.
Immunocytochemical staining
Indirect immunofluorescence was performed as described [15,
17]. Section from frozen tissues, 3 jrm thick, were reacted with the
primary antibody, then incubated with the appropriate secondary
antibody which was preabsorbed with normal human plasma. The
negative control consisted of substituting the primary antibody
with an irrelevant IgG mouse monoclonal antibody, non-immune
rabbit serum, and PBS. In each section containing at least 4
glomeruli (the number of glomeruli examined ranged from 4 to 21
with a mean of 10.1), we counted all the glomerular cells
immunoreactive for Bcl-2, Fas antigen, and PCNA. The popula-
tion of positive cells was expressed as the number of reactive cells
per glomerular cross section.
Double fluorochrome immunofluorescence was performed as
follows [15]: Bcl-2 or Fas antigen was identified with FITC-labeled
goat anti-mouse IgG, and type IV collagen was stained with
rhodamin-labeled goat anti-rabbit IgG.
To demonstrate the intracellular localization of Bcl-2 protein,
immunoelectron microscopy was performed using a pre-embed-
ding method with peroxidase-labeled secondary antibody, as
previously described [15]. Control sections were stained with
nonimmune mouse serum or an irrelevant mouse monoclonal
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sections were digested with DNase before processing [18]. The
omission of either TdT or its biotinylated substrate gave com-
pletely negative results.
In situ hybridization
Fig. 4. A. In situ DNA nick end-labeling in tissue sections from patients with
IgA nephritis. Positive cells are designated by arrowheads. B. In Situ
hybridization for Bcl-2 mRNA in tissue sections from patients with IgA
nephritis. cDNA probe was labeled with digoxigenin-UTP and localized
with anti-digoxigenin antibody conjugated with alkaline phosphatase. The
nitroblue tetrazolium color reaction yielded a purple-brown precipitate in
the intraglomerular cells (arrowheads). (no counter staining, A and B, X
400). Abbreviation is G, glomerulus. Short arrows denote the Bowman's
capsule.
antibody, or secondary antibody alone. These controls were
negative.
In situ DNA nick end labeling
The sections were fixed in 4% paraformaldehyde-lysine-perio-
date. DNA was nick end labeled as described by Gavrieli,
Sherman and Ben-Sasson [18]. In brief, the slides were washed
with distilled water, incubated with 2% H202 to block endogenous
peroxidase, washed with distilled water, and immersed in terminal
deoxy-transferase (TdT) buffer (30 mrvi Tris-HCI buffer, pH 7.2,
100 m sodium cacodylate, 1 m cobalt chloride). The tissues
were then covered with biotinylated dUTP (0.04 nmo1/.d) and
TdT (0.3 U4d) in TdT buffer, and were incubated at 37°C for 90
minutes. After terminating the reaction with 300 m sodium
chloride-30 mM sodium citrate, the slides were washed with
distilled water, incubated with 2% bovine serum albumin, and
reacted with peroxidase-labeled streptavidin (diluted 1:10 to 1:20
in PBS) at room temperature for 30 minutes. The reaction was
visualized using diaminobenzidine-H202. As a positive control,
Hybridization with a digoxigenin-labeled Bcl-2 cDNA probe
(Oncogene Science, Inc.) proceeded as described [19]. In brief,
tissues fixed in 4% paraformaldehyde were cut into 4 j.tm thick
sections, and mounted on slides coated with 3-aminopropyltri-
ethoxysilane (Merck, Darmstadt, Germany). Endogenous alkaline
phosphatase was inactivated with 0.2 N HCI, then the sections
were acetylated with 0.25% acetic anhydride in 0.1 M triethanol-
amide, pH 8.0 for 10 minutes, followed by two 5-mm rinses with
0.1 M phosphate buffer (PB). They were finally dehydrated with an
ethanol series and dried. Prehybridization and hybridization pro-
ceeded in 50% formamide, 2 x SSC (1 x SSC 0.15 M NaC1, 15
m sodium citrate), 1 mg/ml E. coli tRNA, 1 mg/mI sonicated
salmon sperm DNA, 0.1% bovine serum albumin, and 10%
dextran sulfate. After prehybridization at 42°C for 30 minutes, a
hybridization solution containing I to 5 nglml of eDNA probe was
applied to the section, which was then covered with Parafilm and
hybridized at 42°C overnight in a moist chamber. The next day,
the slides were washed briefly with 5 X SSC, followed by 50%
formamide, 2 X SSC at 42°C for 20 minutes, incubated at 37°C for
30 minutes in 20 mg/mi RNase A to remove unbound probe, then
stringently washed in 0.2 X SSC at 42°C for 20 minutes twice.
Hybridized digoxigenin-labeled probe was identified using the
Nucleic Acid Detection Kit (Boehringer Mannheim GmbH)
according to the manufacturer's instructions. Sections were
mounted in glycerin and coverslips were applied. Controls in-
cluded: (i) RNase A digestion (20 .tg/ml) prior to hybridization
for 30 minutes at 37°C; (ii) preincubation with tenfold excess of
unlabeled probe prior to hybridization; (iii) the absence of labeled
cDNA probe and the antidigoxigenin antibody. There were no
positive signals from any of the controls.
Statistical analysis
The data were analyzed using the Mann-Whitney test, the
Kruskal-Wallis test, and Spearman's rank co-efficients. P < 0.05
was considered statistically significant.
Results
Fas antigen expression and apoptosis
Only small number of glomerular cells were labeled for Fas
antigen in normal kidney specimens (Fig. 1). Tissues from patients
with glomerular diseases showed various number of glomerular
cells positive for Fas antigen. By double staining or staining using
serial sections, Fas antigen-positive cells were present in the
mesangial area and within the glomerular capillary walls (Fig. 2 A,
B). These cells were occasionally labeled for LCA.
Electron microscopy was performed upon 12 tissues (8 with IgA
nephritis and 4 with lupus nephritis), which were selected because
Fas-positive cells were detected by immunofluorescent staining.
Condensed nuclei and apoptotic bodies were observed within the
mesangial areas and the glomerular capillaries (Fig. 3).
In situ nick end labeling was carried out in 24 tissues (Fig. 4A).
The data correlated well with the glomerular population of
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Expression of Bcl-2
Normal kidney specimens contained only small number of
Bcl-2-positive cells within the glomeruli (Fig. 1). Double staining
or staining on serial sections showed that Bcl-2-positive cells were
localized mostly in the mesangial area (Fig. 2C, D). They were
occasionally present within the glomerular capillary lumens (Fig.
2 C, D), and labeled for LCA. Immunoelectron microscopy
showed that the Bcl-2 protein was localized in intracellular
organelles of the mesangial cells (Fig. 6A) and leukocytes infil-
trating glomeruli (Fig. 6B). Bcl-2 mRNA was detected in glomer-
ular cells by in situ hybridization (Fig. 4B). The number of
intraglomerular cells positive for Bcl-2 protein weakly correlated
with that of intraglomerular cells stained for Fas antigen (Fig. 5B).
Staining using serial sections showed that Bcl-2-positive cells
generally differed from cells expressing Fas antigen.
Fas antigen or Bcl-2 expression and type of glomerular disease
Among disease categories, the number of Fas antigen-positive
intraglomerular cells was high in glomeruli of patients with
Henoch-SchOnlein purpura nephritis and lupus nephritis, com-
pared with that in the glomeruli of normal kidneys and of patients
with other types of glomerular diseases. That of Bcl-2-positive
intraglomerular cells was high in lupus nephritis, IgA nephritis,
and focal glomerular sclerosis (Fig. 1).
Correlation of Bcl-2 or Fas antigen expression with renal pathology
and clinical findings
A statistical analysis was performed upon data from patients
with mesangial proliferative types of glomerulonephritis, includ-
ing IgA nephritis, IgA-negative mesangial proliferative glomeru-
lonephritis, and Henoch-Schönlein purpura nephritis. The popu-
lation of Bcl-2-positive glomerular cells was significantly
correlated with the number of PCNA-positive intraglomerular
cells (P < 0.001, Fig. 5C), the grade of the mesangial cell increase
(P < 0.005, Fig. 5D), and the magnitude of proteinuria (P < 0.01),
but not with the grade of hematuria. The relationship between Fas
antigen-positive glomerular cells and those parameters was not
statistically significant.
Discussion
The Fas antigen-Fas ligand system mediates apoptotic cell
death in several types of cells [20]. In contrast, the Bcl-2 gene
promotes cell survival by blocking programmed cell death and its
morphological equivalent apoptosis [7—9]. Here we described the
local expression of Fas antigen and Bcl-2 in human glomerulone-
phritis for the first time. We found that the mesangial cells as well
as infiltrating leukocytes express these apoptosis-related proteins.
Among the disease categories studied, the population of Fas
antigen-positive cells was high in tissues from patients with
Henoch-Schönlein purpura nephritis and lupus nephritis, com-
pared with that in normal specimens and tissues from patients
with other types of glomerular diseases. The number of Bcl-2
positive cells was high in lupus nephritis, focal glomerular sclero-
sis, and IgA nephritis. Previously, Harrison [3] briefly described
the presence of apoptotic bodies in glomeruli of patients with
proliferative glomerulonephritis. Observations from experimental
models of glomerulonephritis [4, 5, 21] have indicated that










































Fig. 5. A. Correlation between the number of Fas
antigen-positive celts per glomerular cross-section
(horizontal axis) and that of glomerular cells
stained by in situ nick end labeling (vertical axis)
in tissues from patients with various types of
glomenilar diseases. Each circle represents a
single patient. B. Correlation between the Bcl-2
positive cells per glomerular cross section
(horizontal axis) and Fas antigen-positive
glomerular cells (vertical axis) in tissues from
patients with various types of glomerular
diseases. C. Correlation between Bcl-2 positive
glomerular cells (horizontal axis) and PCNA-
positive glomerular cells (vertical axis) in tissues
from patients with mesangial proliferative types
of glomerulonephritis (IgA nephritis, IgA-
negative mesangial proliferative
glomerulonephritis, and Henoch-Schonlein
purpura nephritis). D. The relationship between
Bcl-2-positive glomerular cells (vertical axis)
and the mesangial hypercellularity (graded
semiquantitatively upon light microscopy, see
Methods) (horizontal axis) in tissues from
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Fig. 6. Ultrastructural observation of Bcl-2
protein in glomendi of a patient with IgA
nephritis, stained with monoclonal antibody to
Bcl-2 protein and peroxidase-conjugated
secondary antibody. Reaction products are seen
in intracellular organelles of one mesangial cell
(A) and a leukocyte infiltrating a glomerulus
(B). Original magnification: X 8,000.
Abbreviations are: BM, basement membrane in
the paramesangial zone (A) and the glomerular
capillary (B); En, glomerular endothelial cell; L,
leukocyte; MC, mesangial cell.
appears that these processes play a role in limiting neutrophil-
mediated glomerular injury and in recovery from mesangial cell
proliferation.
In glomerulonephritis induced by anti-thymocyte antibodies,
mesangial cell proliferation and extracellular matrix accumulation
are transient, and mesangial lesions in most glomeruli resume
their original structures around 6 to 10 weeks after disease
induction [4]. Shimizu et a! 5] have indicated that proliferated
glomerular cells regress by apoptosis in the recovery phase of this
model. In contrast, prolonged mesangial cell proliferation with
increased mesangial matrix is a key feature of chronic forms of
human glomerulonephritis. We speculate that there is a mecha-
nism which suppresses the apoptosis, leading mesangial cells to
continuous proliferation. The Bcl-2 gene is representative of a
category of protooncogenes that function in the regulation of
programmed cell death or apoptosis.
The principal product of the Bcl-2 gene is a 26 kD protein that
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envelope, and parts of the endoplasmic reticulum [8, 22]. The
Bcl-2 gene is normally expressed in long lived or proliferating cell
zones of apoptotic tissues such as the thymus, skin, intestines, and
brain [12, 231. Studies using leukemia or lymphoma cell lines have
shown that Bcl-2 interferes with the apoptotic process mediated
by the Fas antigen and the TNF receptor [24, 25]. Immunohisto-
chemical studies show that Bcl-2 expression is up-regulated in the
human fetal kidney, and suggest that a potential role for Bcl-2
expression during morphogenesis and differentiation of the devel-
oping nephron [101. In fact small kidneys with polycystic kidney-
like change of renal tubules is observed in Bcl-2 knock-out mice
[26]. Bcl-2 expression in the normal adult kidney is not a
consistent finding [10, 231. The results of this study provided a
detailed description of the distribution of Bcl-2 protein in tissues
from patients with glomerular diseases. Bcl-2 mRNA was identi-
fied within the glomeruli, and its protein was detected within
mesangial cells and occasionally infiltrating leukocytes. Bcl-2
expression correlated well with PCNA staining and glomerular
hypercellularity, indicating an association between Bcl-2 expres-
sion and glomerular cell proliferation. These data suggest that a
Grant-in-aid of the Japanese Medical Association (K.Y), a Grant-
in-aid for Scitentific Project (A07770623) from the Ministry of
Education (H.M.), Bcl-2 plays a role in the persistent proliferation
of intrinsic glomerular cells and prolonged survival of infiltrating
leukocytes in human glomerulonephritis. Manipulations of Bcl-2
expression in glomerular cell with gene technology could reveal
the exact role of this gene in the pathogenesis of glomerulone-
phritis.
Recently, a protein with a partial sequence homology with
Bcl-2, termed Bax, has been described. This protein seems to
oppose the action of the Bcl-2 protein. Further studies to eluci-
date the exact role of Bcl-2 overexpression and also the functional
association between Bcl-2 and Bax in glomerulonephritis are
necessary.
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